Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.

Abstract

A focused review of the risk of harms of anti-TNF inhibitors in adult rheumatic diseases was performed. An increased risk of serious infections, tuberculosis and other opportunistic infections has been reported across various studies, with etanercept appearing to have a modestly better safety profile in terms of tuberculosis and opportunistic infections, and infliximab posing a higher risk of serious infections. Evidence suggests no increase in risk of cancer with anti-TNF biologics, but there is an increased risk of non-melanoma skin cancer. Elderly patients appear to be at increased risk of incident or worsening heart failure with anti-TNF biologic use.

• Authors: Archana Jain, Jasvinder A Singh
• Journal: Immunotherapy (Immunotherapy) Vol. 5 Issue 3 Pg. 265-99 (Mar 2013) ISSN: 1750-7448 [Electronic] England
• PMID: 23444956 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antirheumatic Agents
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha
• Infliximab
• Etanercept

Topics

• Adult
• Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use)
• Antirheumatic Agents (administration & dosage, adverse effects, therapeutic use)
• Clinical Trials as Topic
• Etanercept
• Humans
• Immunoglobulin G (administration & dosage, adverse effects)
• Infliximab
• Opportunistic Infections (epidemiology, etiology)
• Receptors, Tumor Necrosis Factor (administration & dosage)
• Rheumatic Diseases (drug therapy)
• Tuberculosis (epidemiology, etiology)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)